Send mail to Author

Correction : phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (Article)

Please indicate your contact information and select, which author you want to contact.



 
 _____       ___      ______   __   __  __    __   __   __  
|  __ \\    / _ \\   /_____//  \ \\/ // \ \\ / //  \ \\/ // 
| |  \ ||  | / \ ||  `____ `    \ ` //   \ \/ //    \ ` //  
| |__/ ||  | \_/ ||  /___//      | ||     \  //      | ||   
|_____//    \___//   `__ `       |_||      \//       |_||   
 -----`     `---`    /_//        `-`'       `        `-`'   
                     `-`
 


Back to frontdoor view

OPUS4 Logo